Compare · ISNS vs TMO
ISNS vs TMO
Side-by-side comparison of Image Sensing Systems, Inc. (ISNS) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- ISNS operates in Capital Goods, while TMO operates in Industrials - the two are in different parts of the market.
- TMO carries a market cap of $225.41B.
- TMO has hit the wire 6 times in the past 4 weeks while ISNS has been quiet.
- TMO has more recent analyst coverage (25 ratings vs 0 for ISNS).
- Company
- Image Sensing Systems, Inc.
- Thermo Fisher Scientific Inc
- Price
- $6.51+2.12%
- $469.57+0.63%
- Market cap
- -
- $225.41B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 1995
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest ISNS
- Image Sensing Systems, Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form 4: Berger Andrew was granted 795 units of Common Stock, increasing direct ownership by 0.69% to 115,293 units
- SEC Form 4: Kruglick Ezekiel was granted 262 units of Common Stock, increasing direct ownership by 0.14% to 187,521 units
- SEC Form 4: Vanderbosch Brian was granted 795 units of Common Stock, increasing direct ownership by 31% to 3,347 units
- SEC Form 4: Daly Joseph Patrick was granted 795 units of Common Stock, increasing direct ownership by 0.60% to 133,459 units
- SEC Form 4: Davis Geoffrey Clark was granted 795 units of Common Stock, increasing direct ownership by 3% to 31,130 units
- SEC Form 4: Lidsky Paul F bought 795 units of Common Stock, increasing direct ownership by 2% to 52,436 units
- SEC Form 4: Bracke James W was granted 795 units of Common Stock, increasing direct ownership by 0.86% to 93,457 units
- SEC Form 3: New insider Kruglick Ezekiel claimed ownership of 187,259 units of Common Stock
- Image Sensing Systems, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits
Latest TMO
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Thermo Fisher Scientific Reports First Quarter 2026 Results
- AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
- Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics
- SEC Form DEFA14A filed by Thermo Fisher Scientific Inc
- SEC Form DEF 14A filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 23, 2026
- SEC Form 4 filed by Sperling Scott M
- SEC Form 4 filed by Keith R. Alexandra
- SEC Form 4 filed by Lynch Karen S